Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

NCT00874588 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2

Sponsor

Fukushima Medical University

Collaborators

[object Object]